Gravol (Dimenhydrinate): Clinical Overview
Indications
Gravol is primarily indicated for motion sickness prevention and treatment, with additional off-label uses for nausea and vomiting from various causes 1. The drug contains dimenhydrinate 50 mg as its active ingredient 1.
Primary Indication
- Motion sickness prevention and treatment 1
Off-Label Uses Supported by Evidence
Postoperative nausea and vomiting (PONV): Dimenhydrinate demonstrates comparable efficacy to ondansetron for PONV prevention in laparoscopic cholecystectomy, with 34% requiring rescue antiemetics versus 29% with ondansetron 2. Multiple-dose regimens (62 mg IV repeated 3 times over 48 hours) reduce severe PONV from 39.4% to 14.9% 3.
Chemotherapy-induced nausea/vomiting: Listed as a breakthrough treatment option in NCCN guidelines, though not a first-line agent 4
Radiation-induced emesis: Can be used for breakthrough treatment 4
Gastroenteritis-related vomiting: Reduces vomiting episodes (69.6% vomit-free versus 47.4% with placebo), though does not improve overall clinical outcomes or oral rehydration success 5
Vertigo with nausea: Equivalent efficacy to metoclopramide, reducing vertigo VAS scores from 7.57 to 2.46 at 30 minutes 6
Recommended Dosing
Motion Sickness Prevention 1
Take the first dose 30-60 minutes before activity begins
Adults and children ≥12 years: 50-100 mg (1-2 capsules) every 4-6 hours
- Maximum: 400 mg (8 capsules) per 24 hours
Children 6 to <12 years: 50 mg (1 capsule) every 6-8 hours
- Maximum: 150 mg (3 capsules) per 24 hours
Off-Label Dosing from Research
- PONV prevention: 62 mg IV after anesthesia induction, repeated 3 times over 48 hours 3
- Breakthrough nausea/vomiting: Not specifically dosed in guidelines, but research supports 50-100 mg IV 2, 6
- Vertigo: 50 mg IV over 15 minutes 6
Contraindications and Precautions
Absolute Contraindications
- Hypersensitivity to dimenhydrinate or antihistamines
Critical Precautions
Use with extreme caution or avoid in patients on anticholinergic medications (e.g., sertraline), as this combination can trigger acute urinary retention requiring catheterization 7.
Avoid during active labor: IV dimenhydrinate 100 mg significantly increases uterine activity and causes hypoxic-type fetal heart rate decelerations in 20% of cases 8.
High abuse potential exists: Chronic high-dose use (2400 mg/day) causes euphoria, anxiolysis, and hallucinations due to anticholinergic properties, with documented cases of addiction requiring medical detoxification 9. Long-term abuse may contribute to irreversible cognitive impairment even in younger patients 10.
Specific Populations Requiring Caution
- Elderly patients: Anticholinergic burden increases dementia risk
- Patients with urinary retention risk: Prostatic hypertrophy, bladder outlet obstruction
- Patients with psychiatric disorders: Potential for abuse and psychotropic effects
- Patients requiring CNS performance: Causes dose-dependent sedation
Common Adverse Effects
Sedation Profile
Sedation is the most clinically significant adverse effect, with severity dependent on formulation and dosing pattern. Fast-release tablets cause significantly greater CNS depression than divided-dose formulations (chewing gums), as measured by auditory evoked potentials and complex choice reaction times 11.
Documented Adverse Effects from Clinical Trials
Common (>10%)
- Sedation/drowsiness
- Dizziness
Occasional (1-10%)
- Hypotension (no significant difference from placebo in ED studies) 6
- Dry mouth (anticholinergic effect)
- Blurred vision
Rare but Serious
- Acute urinary retention (especially with concurrent anticholinergic medications) 7
- Fetal distress during labor (hypoxic decelerations in 20% of cases) 8
- Cognitive impairment with chronic high-dose use 10
- Withdrawal syndrome: Severe nausea, vomiting, sedation, headaches, dizziness, anxiety, muscle stiffness (managed with benztropine and lorazepam) 9
Comparative Safety
In PONV studies, side effect profiles were similar between dimenhydrinate and ondansetron, with no significant differences in sedation or hypotension rates 2, 6.
Clinical Pearls and Pitfalls
Cost-effectiveness: Dimenhydrinate ($2.50/dose) provides equivalent PONV prophylaxis to ondansetron ($17/dose), potentially saving $7.25 million annually in the US for laparoscopic cholecystectomies alone 2.
Formulation matters for CNS effects: Divided-dose or slow-release formulations significantly reduce sedation while maintaining antiemetic efficacy 11.
Limited benefit in gastroenteritis: While reducing vomiting frequency, dimenhydrinate does not improve weight gain, oral rehydration success, or hospital admission rates in pediatric gastroenteritis—the overall clinical benefit is low 5.
Screen for abuse: Monitor patients with psychiatric histories or chronic pain conditions for escalating doses or non-oral routes of administration 9.
Drug interactions: Particularly dangerous with other anticholinergic agents (TCAs, antihistamines, antipsychotics, SSRIs) due to additive effects 7.